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The chemokine MCP-1/CCL2 is produced by a variety of tumors and plays an important
role in cancer progression. We and others previously demonstrated that the primary
source of MCP-1 in several mouse tumors, including 4T1 breast cancer, M5076 sarcoma,
and B16 melanoma, was stromal cells. In the present study, we identified that tumor
cells were the primary source of MCP-1 in Lewis lung carcinoma (LLC), because MCP-1
mRNA was highly expressed in tumors grown in both wild type (WT) and MCP-1 / 
mice with elevated serum MCP-1 levels. Since LLC cells isolated from tumors expressed
low levels of MCP-1 in vitro, it appeared that the tumor–stromal cell interaction in a
tumor microenvironment increased MCP-1 expression in LLC cells. In fact, co-culture
of LLC cells with normal mouse peritoneal macrophages or normal lung cells containing
macrophages increased MCP-1 expression by LLC cells. Macrophages from TNFα / 
mice failed to activate LLC cells and anti-TNFα neutralizing antibody abolished the effect
of WT macrophages on LLC cells. When LLC cells were transplanted into TNFα /  mice,
the levels of MCP-1 mRNA in tumors and serum MCP-1 levels were markedly lower
as compared to WT mice, and importantly, tumors grew more slowly. Taken together,
our results indicate that TNFα released by tumor cell-activated macrophages is critical
for increased MCP-1 production by tumors cells. Thus, disruption of tumor–stromal cell
interaction may inhibit tumor progression by reducing the production of tumor-promoting
proinflammatory mediators, such as MCP-1.
Keywords: monocytes/macrophages, chemokines, inflammation, tumor microenvironment, lung cancer
Introduction
Tumor tissues consist of a variety of cell types, including tumor cells, fibroblasts, endothelial cells,
myocytes, and inflammatory cells, such as myeloid-derived suppressor cells, regulatory T cells,
macrophages, and dendritic cells. The interaction of tumor cells with stromal cells leads to the
production of an array of mediators that provide the soil for tumor cells to grow, invade, and
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metastasize. These mediators include matrix metalloproteinases,
growth factors, cytokines, and chemokines (1–3).
MCP-1/CCL2 is a chemokine with potentmonocyte chemotac-
tic activity. It was initially purified from the culture supernatant of
a human malignant glioma cell line (4) and a human monocytic
leukemic cell line (5), and found to be identical to the previously
described tumor cell-derived chemotactic factor (6). Although
earlier animal studies using MCP-1-transfected tumor cells pro-
vided a combination of anti- or pro-tumor effects of MCP-1
(7–10), accumulating evidence strongly supports the notion that
the production ofMCP-1 by tumors promotes tumor progression.
A study of a chemically induced skin papilloma showed a lower
number of papillomas developing in MCP-1 /  mice compared
to wild type (WT) mice (11). A critical role of MCP-1 in the ini-
tiation and progression of colitis-associated colon carcinogenesis
was demonstrated by using mice deficient in the MCP-1 receptor
CCR2 or MCP-1 blocking agents (12). Furthermore, neutraliza-
tion of MCP-1 resulted in reduced growth of prostate (13–15) and
lung cancer (16), as well as reducedmetastasis of breast cancer (17,
18) in mice.
In humannon-small cell lung cancer (NSCLC), elevatedMCP-1
production was previously reported (19, 20). Increased number
of tumor infiltrating macrophages, likely regulated by increased
MCP-1 production, corresponded to a shorter survival rate of
NSCLCpatients (19). In contrast, in another study,MCP-1 expres-
sion in cancer cells was associated with better survival in NSCLC
patients (20). Recent studies using mouse NSCLC models indi-
cated a role for MCP-1 in the progression of NSCLC. Lewis
lung carcinoma (LLC) is a NSCLC cell line (21), which con-
stitutively produces MCP-1 in vitro and the production can be
highly upregulated in response to the TLR4 ligand LPS or TNFα
(22, 23). Intrapleural injection of LLC cells induced malignant
pleural effusion through MCP-1 production (22) and neutraliza-
tion of MCP-1 reduced the growth of subcutaneously injected
LLC cells (16). These animal studies strongly suggest a critical
role of MCP-1 in the development of NSCLC. Thus, MCP-1 is a
candidate molecular target of cancer treatment (24) and recent
clinical trials using a neutralizing anti-MCP-1 antibody showed
some anti-tumor efficacy (25, 26).
There are three potentialmechanisms bywhichMCP-1 produc-
tion is increased in tumors: (1) tumor cells constitutively produce
a high level of MCP-1, (2) tumor cells produce a high level of
MCP-1 in response to stimuli, and (3) stromal cells produce a
high level of MCP-1 in response to stimuli, such as a tumor cell
product(s). Tumor cells were originally thought to be the primary
source of MCP-1 in established tumors (4–6); however, recent
studies indicated that stromal cells were the primary cell source of
MCP-1 in some mouse tumor transplantation models, including
4T1 breast cancer (23), M5076 sarcoma, and B16 melanoma (27).
In the present study, we aimed to examine the mechanisms
of MCP-1 production in a mouse LLC transplantation model.
We found that in established LLC tumors, tumor cells were the
primary source of MCP-1. We further revealed that LLC cells
activate macrophages to produce TNFα which, in turn, markedly
increasesMCP-1 production byLLCcells. Thus, crosstalk between
tumor cells and stromal cells plays a major role in the produc-
tion of proinflammatory, tumor-promoting mediators in a tumor
microenvironment, which constitutes a plausible target for anti-
cancer therapy.
Materials and Methods
Mice
Wild type C57BL/6 and Balb/c mice were from Charles River,
Frederick, MD, USA. The generation of C57BL/6 or Balb/c
MCP-1 /  [MMRRC stock No. 037094-UNCC, 29S1(Cg)-
Ccl2tm1.1Tyos/Mmnc] was previously described (23, 28).
Myeloid cell-specific MCP-1 /  mice were generated by crossing
MCP-1flox/flox mice (JAX Stock No. 023347, B6; 129-Ccl2
<tm1Tyos>/J) (28, 29) to LysMCre mice (30). MyD88 / ,
TLR2 / , TLR4 / , TLR9 / , and IL-1R1 /  mice on a
C57BL/6 background were from the Cancer and Inflammation
Program Mouse Core, NCI, Frederick. Mouse resident peritoneal
cells (PC) were obtained by flushing the peritoneal cavity of
C57BL/6 mouse with 5ml clod PBS. Mouse peritoneal exudates
cells (PEC) were induced by intraperitoneal injection of 3%
thioglycollate (TG) (Difco Laboratory, Detroit, MI, USA). PEC
were harvested 3–4 days later by flushing the peritoneal cavity
with 5ml clod PBS. The experimental protocols of this study
were approved by the Frederick National Laboratory for Cancer
Research Animal Care and Use Committee, Frederick, MD, USA.
Tumor Transplantation Model
LLC, 4T1, and B16F1 cells were obtained from American Type
Culture Collection (ATCC) and maintained in National Cancer
Institute DCTD Tumor Repository. All cell lines were tested for
their mouse origin by using the Molecular Testing of Biologi-
cal Materials assays by Animal Health Diagnostic Laboratory at
National Cancer Institute-Frederick in 2009. LLC and 4T1 cells
were cultured in RPMI 1640 (Lonza, Walkersville, MD, USA)
supplemented by 10% fetal bovine serum (FBS, HyClone, Rogan,
UT, USA), 100µM glutamine, 1 penicillin/streptomycin, and
1mM sodium pyruvate. B16F1 cells were cultured in DMEM
(Lonza) supplemented by 10% FBS, 100µM glutamine, 1 peni-
cillin/streptomycin, and 1mMsodiumpyruvate, 1non-essential
amino acid, 1MEM vitamins. Cells were grown to 50–80% con-
fluence. Before injection, cells were detached with 0.2% trypsin-
EDTA, washed once with medium, three times with PBS, and
resuspended in PBS at 4 106/ml for LLC and 1 106/ml for 4T1
or B16F1 cells. One hundred microliters of cell suspension were
injected into the flank for LLCor B16F1 and themammary pad for
4T1 cells. Tumor size was measured and tumor volume was calcu-
lated using the following formula: Volume= (width)2 length/2.
To generate LLC tumors in the lung, 105 LLC cells in 100µl PBS
were intravenously injected and tumors were harvested 2weeks
after injection.
To evaluate the level of MCP-1 mRNA expression, mice were
euthanized and then tumors were excised and stored in RNAlater
(Ambion). Blood was drawn by heart or mandibular puncture.
Sera were isolated and stored at 80°C until use.
To recover tumor cells from tumors, tumors were excised,
minced, and digested with collagenase VI (Sigma-Aldrich, St.
Louis, MO, USA) for 3 h at room temperature. After removal of
tissue debris, cells were rinsed with RPMI 1640 containing 10%
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FBS, and then plated in a tissue culture plate. Cells were passed
for five generations at 1:5 before used. At this stage, the mutated
MCP-1 allele was no longer detectable by PCR in tumor cells
harvested from the tumor of MCP-1 /  mice, indicating that
there was no significant contamination by host cells.
In vitro Culture
One hundred thousand or 1 103 LLC in 1ml medium were
seeded into six-well or 12-well tissue culture plates, respectively.
After overnight incubation at 37°C, medium containing non-
adherent cells was removed and replaced by 2ml fresh medium.
PC or PEC in 50µl medium was added to the wells or culture
insert and the plates were incubated for 2 or 5 days.
Lungs harvested from MCP-1 /  mice were minced using the
gentle MACS Dissociator (Miltenyi Biotec, Inc., Auburn, CA,
USA), and then digested with collagenase VI for 2–3 h at room
temperature. Tissue debris was removed, red blood cells were
lysed, and the resulting lung cells were seeded into 12-well tissue
culture plates, and then co-cultured with 1 103 LLC cells for
5 days.
To activate tumor cells, 1 105 tumor cells were seeded into
12-well tissue culture plates. After overnight incubation at 37°C,
medium was removed and 1ml of fresh medium was added and
cells were incubated at 37°C in the presence or absence of 1 or
10 ng/ml recombinantmouse TNFα (R&D Systems,Minneapolis,
MN, USA) or 100 ng/ml lipopolysaccharide (LPS, Sigma-Aldrich,
St. Louis, MO, USA). Total RNA was extracted by TRIzol (Life
Technologies, Grand Island, NY, USA). Cell-free culture super-
natants were also prepared and kept at 80°C until use.
Flow Cytometry
After blocking Fc receptors, cells were incubated with appropri-
ately diluted anti-mouse antibodies, including PE-F4/80 (BM8),
PerCP-CD45 (30-F11), andAPC-CD11b (M1/70) (Biolegend, San
Diego, CA, USA). Appropriate species matched Abs served as
isotype control. Acquisition of data was performed using a LSRII
(BDBiosciences,MountainView, CA,USA), and data analysis was
conducted using the FlowJo software (Tree Star Inc., Ashland, OR,
USA). Only live cells determined using LIVE/DEADFixable Dead
Cell Stain Kit (Life Technologies, Grand Island, NY, USA) were
analyzed.
Northern Blotting
Northern blot analysis was performed as described with a minor
modification (28, 31). Filters were hybridized at 42°C overnight in
ULTRAhyb (Life Technologies) with 106 dpm/ml of cDNA probe
labeled by 32P (Perkin Elmer, Cambridge, MA, USA). Filters were
washed twice with 2 SSC, 0.1% SDS at room temperature for
15min, and once with 0.1 SSC, 0.1% SDS at 60°C for 30min
prior to autoradiographic exposure.
Gene Expression Profiling
The profile of gene expression was analyzed using the nCounter
Analysis System (NanoString Technologies, Seattle, WA, USA)
(32). The nCounter Code Set for the study contained 41 test
and two control genes. The assay used two sequence-specific
probes for each gene of interest. The probes were complemen-
tary to a 100-base region of the target mRNA. One probe was
covalently linked to an oligonucleotide containing biotin (the
capture probe); the other was linked to a color-coded molecular
tag (reporter probe). Each hybridization consisted of 100 ng of
total RNA, reporter, and capture probe mix for the 43 genes. The
hybridization, washing, and scanning procedures were conducted
according to the guidelines provided byNanoString Technologies.
ELISA
The concentrations of MCP-1 were measured with an ELISA kit
specific for mouse MCP-1 (R&D Systems). The sensitivity of the
assay was 2 pg/ml.
Statistical Analysis
All experiments were performed at least twice. Results presented
were from representative experiments. Statistical analysis was per-
formed by Student’s t-test or log-rank (Mantel-Cox) test, using
the GraphPad Prism, Version 4, 5, or 6, GraphPad Software,
San Diego, CA, USA. A value of p< 0.05 was considered to be
statistically significant.
Results
Activated Tumor Cells are the Main Source of
MCP-1 in LLC Tumors
It was previously demonstrated that the blockade of MCP-1 sig-
nificantly slowed the growth of primary tumors in mouse NSCLC
models, including a LLC model (16). To evaluate the role for
MCP-1 produced by non-tumor stromal cells in tumor growth in
this model, we subcutaneously injected LLC cells into the flank of
WT or MCP-1 /  mice. As shown in Figure 1A, tumors grew at
a similar rate in both WT and MCP-1 /  mice, indicating that
the lack of MCP-1 in stromal cells does not interfere with tumor.
Compared to in vitro cultured LLC cells (Figure 1B, lane 1),
much higher levels of MCP-1 mRNA were detected in all tumors
from both WT (lanes 2–6) and MCP-1 /  mice (lanes 7–11).
SerumMCP-1 levels were also elevated in tumor-bearingWT and
MCP-1 /  mice (Figure 1C).
Lewis lung carcinoma is a lung cancer cell line (21). To examine
whether LLC tumors formed in the lung also express high levels of
MCP-1,we intravenously injectedLLCcells andexamined the level
ofMCP-1mRNAin lungmetastatic tumors 2weeks after injection.
As shown inFigure1D, lung tumors formed inbothWTandMCP-
1 / mice expressed high levels ofMCP-1mRNA (lanes 2, 3, 5, 6).
Since tumor tissues contained a significant amount of lung tissue
that expressed only a low level of MCP-1 (lanes 4, 7), the levels
of MCP-1 mRNA detected in lung tumors were lower than those
in subcutaneous tumors. Serum MCP-1 levels were also elevated
in both WT and MCP-1 /  mice which received i.v. injection of
LLC cells (Figure 1E). These results indicate that tumor cells are
the primary source of MCP-1 in LLC tumors.
We then compared the levels of MCP-1 expressed in LLC
tumors with those in 4T1 or B16 tumors in which stromal cells
were the main source of MCP-1 (23, 27). 4T1 and B16 cells
expressed lower levels ofMCP-1 than LLC cells in vitro (Figure 1F,
lanes 1, 6, 11). As we previously reported, 4T1 tumors grown in
WTmice expressedmoderate levels of MCP-1mRNA (lanes 2, 3),
whereas those in MCP-1 /  mice expressed minimal levels of
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FIGURE 1 | The expression of MCP-1 in 4T1, B16, and LLC tumors
growing in WT or MCP-1 /  mice. (A) Four hundred thousand LLC cells
in 100µl PBS were injected into the flank of female WT or MCP-1 /  mice
and the size of each tumor was measured and the volume was calculated.
The results are shown as the meanSEM; n= 6. (B) The expression of
MCP-1 mRNA was examined by Northern blotting 2weeks after LLC tumor
cell inoculation. (C) Serum MCP-1 concentrations were measured by ELISA
2weeks after LLC tumor cell inoculation. The results are shown as the
meanSEM. n= 4 for non-tumor-bearing WT mice and n=5 for
tumor-bearing WT or MCP-1 /  mice. A summary of two experiments.
(D,E) One hundred thousand LLC cells in 100µl PBS were intravenously
injected into WT or MCP-1 /  mice. Two weeks after injection, blood was
collected by heart punctured and serum was obtained. Lungs were excised
and stored in RNAlater. Total RNA was extracted by TRIzol from lung tumors
or adjacent lung tissues and the expression of MCP-1 mRNA expression
was examined by Northern blotting. Serum MCP-1 concentration was
measured by ELISA. The results are shown as the meanSD. n= 2 for
tumor-bearing WT or MCP-1 /  mice. (F) One hundred thousand 4T1 or
B16 cells in 100µl PBS were injected into the mammary pad or the flank of
WT or MCP-1 /  mice, respectively. Two weeks later, the expression of
MCP-1 mRNA by tumors was evaluated by Northern blotting. (G) The
expression of MCP-1 mRNA in 4T1 tumors and LLC tumors growing in WT
mice was evaluated by Nanostring gene profiling. The results are shown as
the meanSEM.
MCP-1 mRNA (lanes 4, 5). A similar observation was made for
B16 tumors with much lower MCP-1 levels in tumors in WT
mice (lanes 7–10). The levels of MCP-1 mRNA expressed in LLC
tumors were markedly higher compared to 4T1 or B16 tumors
(lanes 12, 13), with approximately 10-fold higher MCP-1 mRNA
in LLC tumors than in 4T1 tumors (Figure 1G).
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There are two possibilities that could explain increased MCP-
1 expression in LLC cells in tumors; one is that tumor cells
constitutively express high levels of MCP-1, and the other is that
tumor cells express high levels of MCP-1 in response to stimuli
present in a tumormicroenvironment.We, therefore, isolated LLC
cells from tumors grown in either WT or MCP-1 /  mice by
culturing in vitro to deplete non-tumor cells, and examined the
level of MCP-1 mRNA. As shown in Figure 2A, high levels of
MCP-1mRNAwere detected in the original tumors grown inWT
or MCP-1 /  mice (lanes 2–5), but the levels of MCP-1 mRNA
expressed by LLC cells isolated from tumors either from WT or
MCP-1 /  mice (mouse #4 and 5 presented in Figure 1B) were
low (lanes 6–9) and comparable to that in the original LLC cells
used for injection (lane 1), supporting the hypothesis that MCP-1
expression is not constitutively elevated in tumor cells, but rather,
activation of tumor cells in a tumor microenvironment is the
cause of elevatedMCP-1 expression by tumor cells in vivo. In fact,
LLC cells, in response to LPS or TNFα, expressed high levels of
MCP-1 mRNA in vitro (Figure 2B, lanes 9–12). We previously
reported that LLC cells produced a high level of MCP-1 protein
in response to these mediators (23). Thus, there was a strong
correlation between the level of MCP-1 mRNA expression and
protein production. In contrast to LLC cells, 4T1 or B16 cells
responded poorly to the same mediators (Figure 2B, lanes 1–8).
FIGURE 2 | The expression of MCP-1 in LLC cells isolated from tumors
and the role of proinflammatory mediators. (A) Four hundred thousand
LLC cells in 100µl PBS were injected into the flank of female WT or
MCP-1 /  mice. Two weeks later, mice were euthanized, and tumors were
excised and cut into halves. One half was stored in RNAlater for total RNA
isolation. The other half was minced and digested with collagenase VI for 3 h
at room temperature. After removal of tissue debris, cells were rinsed with
RPMI 1640 containing 10% FBS, and then plated in a tissue culture plate.
Cells were passed for five generations at 1:5 before use. At this stage, the
mutated MCP-1 allele was no longer detectable by PCR in tumor cells
harvested from MCP-1 /  mice, indicating that there was no significant
contamination by host cells. The expression of MCP-1 mRNA was examined
by Northern blotting. All samples (10µg per lane) were loaded onto a single
gel and RNA was transferred to a single membrane. (B) 4T1, B16, or LLC
cells were stimulated by 100 ng/ml of LPS or 10 or 100 ng/ml of mouse
recombinant TNFα for 6 h. Total RNA was isolated and the expression of
MCP-1 mRNA was examined by Northern blotting.
These results indicate that LLC cells express higher levels ofMCP-
1, once they form tumors in vivo and are exposed to factors in a
tumor microenvironment.
Co-Culture with Macrophages Markedly
Increases MCP-1 Expression by LLC Cells
To analyze the potential mechanisms by whichMCP-1 expression
is elevated in LLC cells in a tumor microenvironment, we co-
cultured 105 LLC cells for 2 days in six-well culture plates with 106
or 2 106 PEC containing mostly inflammatory macrophages, a
cellular component found in tumormicroenvironment. As shown
in Figure 3A, MCP-1 mRNA expression was increased in the co-
cultured cells dependently of the number of PEC (lanes 1–3).
However, this increase was absent when PEC from myeloid cell-
specific MCP-1 /  mice were used in the co-culture (lanes 4, 5),
indicating that under this co-culture condition increased levels of
MCP-1 mRNA were originated from activated macrophages but
not LLC cells. Thus, this co-culture condition did not reflect the
condition found in LLC tumors in vivo.
We next reduced the number of LLC cells to 103 so that the cul-
ture period could be extended to 5 days.We also used resting peri-
toneal macrophages (PC) or TG-induced PEC fromMCP-1 /  to
detectMCP-1mRNAonly fromLLC cells. As shown in Figure 3B,
therewas noMCP-1mRNAexpression in PECofMCP-1 / mice
(lane 1). Interestingly, co-culture with either MCP-1 /  PC or
PEC increasedMCP-1 mRNA expression by LLC cells (lanes 3–8)
with considerably higher MCP-1 expression after co-culture with
PC (lanes 3–5). One million PC or PEC were sufficient to induce
the highest level of MCP-1 mRNA.
To determine whether cell contact is required for increased
MCP-1 expression by LLC cells, LLC cells and PC of WT or
MCP-1 /  mice were either co-cultured together (Figure 3C,
lanes 1–3, 7–9) or separated by a membrane (lanes 4–6, 10–12).
Since PC were more efficient in increasingMCP-1 mRNA expres-
sion by LLC cells, only PC were used. Increased MCP-1 mRNA
expression was detected in both culture conditions with the high-
est MCP-1 mRNA levels obtained with 105 PC, indicating that
direct cell contact is not required. There was also no difference
in the level of MCP-1 mRNA detected in LLC cells co-cultured
with WT (lanes 1–6) or MCP-1 /  (lanes 7–12) PC, excluding
the interference by macrophage-derived MCP-1 mRNA in our
assay system. Consistent with themRNA levels, there was a signif-
icant increase inMCP-1 concentration in the culture supernatants
detected by ELISAwhen LLC cells were co-cultured with as few as
4 103 PC (Figure 3D).
To examine whether macrophages were responsible for the
increased MCP-1 mRNA expression by LLC cells, non-adherent
cells were removed from TG-induced PEC by adherence and
adherent cells were co-cultured with LLC cells. Both total PEC
(Figure 3E, lanes 2, 3) and adherent cells in PEC (lanes 4–7)
increased MCP-1 mRNA expression by LLC cells, strongly sug-
gesting that macrophages were responsible for the increased
MCP-1 expression by LLC cells.
Since LLC cells are originated from lung, we examined whether
lung macrophages could also enhance MCP-1 expression by LLC
cells. As shown in Figure 3F, similar to PC (lane 2), co-culture
of LLC cells with MCP-1 /  mouse lung cells containing an
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FIGURE 3 | The expression of MCP-1 in LLC cells after co-culture with
peritoneal macrophages. (A) One hundred thousand LLC cells were
seeded into six-well plates. After overnight incubation at 37°C, 1106 or
2106 TG-induced PEC from WT or LysMCre+MCP-1flox/flox mice were
added and incubated for an additional 2 days. Total RNA was isolated and
the expression of MCP-1 mRNA was examined by Northern blotting (10µg
per lane). (B) Ten thousand LLC were seeded into six-well plates. After
overnight incubation at 37°C, 1106, 2106 or 5106 PC, or PEC from
MCP-1 /  mice were added and incubated for 5 days. Total RNA was
isolated and the expression of MCP-1 mRNA was examined by Northern
blotting (10µg per lane). (C) One thousand LLC cells were seeded into
12-well plates. After overnight incubation at 37°C, 4103, 2104 or
1105 PC from WT or MCP-1 /  mice were added directly to wells or into
culture inserts. After incubation at 37°C for 5 days, total RNA was isolated
and the expression of MCP-1 mRNA was examined by Northern blotting
(10µg per lane). (D) One thousand LLC cells were seeded into 12-well plates.
After overnight incubation at 37°C, 4103, 2104 or 1105 PC from WT
mice were added directly to wells. After incubation at 37°C for 5 days, the
concentration of MCP-1 in the culture supernatants was measured by ELISA.
The results are shown as the meanSEM. *p<0.001, n= 4. (E) One
hundred or two hundred thousand PEC were seeded into wells of 12-well
plate and incubated at 37°C for 3 h. Non-adherent cells were removed by
gently washing the wells with medium, and then 1103 LLC cells were
added. After incubating at 37°C for 5 days, total RNA was isolated and the
expression of MCP-1 mRNA was examined by Northern blotting (10µg per
lane). (F) One thousand LLC cells were seeded into 12-well plates. After
overnight incubation at 37°C, 1105 lung cells from MCP-1 /  mice were
added directly to the wells. After incubation at 37°C for 5 days, total RNA was
isolated and the expression of MCP-1 mRNA was examined by Northern
blotting (10µg per lane).
approximately 64% CD45+ cell population mostly macrophages
(data not shown), increased MCP-1 mRNA expression by LLC
cells, indicating that the interactionwithmouse lungmacrophages
also increases MCP-1 mRNA expression by LLC cells.
Elevated MCP-1 Expression by Tumor Cells is
Dependent on Macrophage TNFα
TLR ligands activatemacrophages and can be released from tumor
cells. Those activated macrophages then produce proinflamma-
tory cytokines, such as TNFα, in a tumor microenvironment. To
examine whether these proinflammatory mediators are involved
in promoting MCP-1 expression by LLC tumors, we co-cultured
LLC cells with PC fromMyD88 /  or TNFα / mice and exam-
ined MCP-1 mRNA expression or MCP-1 protein production by
LLC cells. PC from WT mice increased MCP-1 mRNA expres-
sion by LLC cells (Figure 4A, lanes 1–4). In contrast, PC from
TNFα / mice (Figure 4A, lanes 8–10, Figure 4B) orMyD88 / 
mice (Figure 4A, lanes 5–7, Figure 4B) did not increase MCP-1
expression or production by LLC cells. Addition of an anti-TNFα
neutralizing antibody in the co-culture of LLC cells and WT PC
almost completely inhibited the effect of WT PC to promote
MCP-1mRNAexpression or production by LLC (Figure 4A, lanes
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FIGURE 4 | The role of macrophage MyD88 and TNFα in MCP-1 mRNA
expression by LLC cells. (A) One thousand LLC cells were seeded into
12-well plates. After overnight incubation at 37°C, three different numbers of
PC from WT, MyD88 /  or TNF /  mice were added to the wells. To
neutralize TNFα, 2 or 10µg of anti-mouse TNFα IgG (R&D Systems) was
added with 1105 PC from WT mouse. After incubation at 37°C for 5 days,
total RNA was isolated and the expression of MCP-1 mRNA was examined
by Northern blotting (10µg per lane). (B) The experiment presented in A was
repeated with 1105 PC from WT, MyD88 /  or TNF /  mice and the
MCP-1 concentration in the culture supernatants was measured by ELISA.
The results are shown as the meanSEM. *p<0.0001, n= 4. (C) The
expression of TNF mRNA in 4T1 tumors or LLC tumors was examined by
Nanostring gene profiling. The results are shown as the meanSEM.
11, 12, Figure 4B). The expression of TNFα mRNA was detected
in both 4T1 and LLC tumors with significantly higher expression
levels in LLC tumors (Figure 4C). Thus, TNFα is available in a
LLC tumor microenvironment.
To evaluate the role for host cell-derived TNFα and MyD88
in vivo, we transplanted LLC cells into the flank of WT,
MyD88 /  or TNFα / mice, and examined the levels ofMCP-1
mRNA in tumors after 2 weeks. Consistent with in vitro results,
the expression of MCP-1 was markedly lower in LLC tumors
grown in TNFα /  mice (Figure 5A, lanes 8–10). SerumMCP-1
levels were also lower in tumor-bearing TNFα /  mice. Impor-
tantly, the volumes of tumors in TNFα / mice were significantly
smaller than those in WT mice (Figures 5B,C). These results
indicate that TNFα is a critical macrophage-derived mediator
that increases the production of MCP-1 by LLC cells in tumors.
Although the expression of MCP-1 was also reduced in LLC
tumors grown in MyD88 /  mice (Figure 5A, lanes 5–7), there
was no significant difference in either serum MCP-1 level or
tumor volume betweenMyD88 /  andWTmice (Figures 5B,C).
Finally, we investigated the mechanistic basis for LLC cells
to induce TNFα production by macrophages. It was previously
demonstrated that LLC cells were able to release an extracellular
matrix protein versican that activated myeloid cells to produce
TNFα via TLR2 (33). MyD88 is a signaling molecule down-
stream of TLR2 and the loss of MyD88 /  in PC reduced MCP-
1 mRNA expression by LLC cells in vitro; therefore, TLR2 on
macrophages may play a role in LLC cell-induced macrophage
TNFα production. Contrary to our hypothesis, however, PC from
TLR2 /  mice (Figure 6A, lane 3) were as efficient as PC from
WT mice (Lane 2) to increase MCP-1 expression by LLC cells.
PC from TLR4 /  or IL-1R1 /  mice (Figure 6B, lanes 5–10)
or TLR9 /  mice (Figure 6C, lanes 5–7) also increased MCP-
1 mRNA expression by LLC cells. Thus, it appears that LLC
cells activate macrophages by a mechanism independent of TLR2,
TLR4, TLR9, or IL1R1 involving MyD88. It is also possible that
LLC cells activate macrophages via more than one TLR.
Discussion
The chemokine MCP-1/CCL2 is involved in multiple stages of
tumor progression, such as recruitment of immunosuppressive,
tumor-promoting M2 macrophages, angiogenesis, tumor inva-
sion, and metastasis. We and others previously demonstrated that
stromal cells, but not tumor cells, were the primary source of
MCP-1 in several mouse tumor models, including 4T1 breast
cancer (23),MO5076 sarcoma, and B16melanoma (27). However,
since many types of tumor cells have been shown to express
MCP-1 in vitro and in vivo (34), tumor cells may also be the
source of MCP-1 in selected tumors. In the present study, we
found that tumor cells were the primary source of MCP-1 in
LLC tumors growing in vivo. We also revealed that LLC cells
activate macrophages to produce TNFα, which in turn, further
increasesMCP-1 production by LLC cells. This is the first demon-
stration that LLC-macrophage interaction may be critical for ren-
dering tumor cells as the primary source of MCP-1 in a tumor
microenvironment.
A number of proinflammatory mediators are present in tumor
microenvironments, among which TNFα is shown to promote
tumor progression potentially by inducing MCP-1 production
inside tumors (11, 35, 36). However, the cellular source of TNFα
and the mechanisms by which TNFα is produced in tumors
remain unclear. Kim et al. found that among cell lines screened,
LLC cells were the most potent macrophage activators leading to
the production of IL-6 and TNFα through activation of TLR2
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FIGURE 5 | The expression of MCP-1 mRNA in LLC tumors
growing in WT, MyD88 /  or TNF /  mice. LLC cells (4105
cells in 100µl PBS) were injected into the flank of female WT,
MyD88 /  or TNF /  mice. Two weeks later, the expression of
MCP-1 mRNA in tumors, the serum MCP-1 concentrations, and the
tumor volumes were analyzed. (A) The level of MCP-1 mRNA
expression in tumors was examined by Northern blotting and quantified
by densitometry. The results are shown as the meanSD. (B) Serum
MCP-1 concentrations were measured by ELISA. The results are shown
as the meanSEM. The summary of two experiments. (C) The volume
of each tumor from each group was calculated and compared. The
results are shown as the meanSEM.
and TLR6. Both TNFα and TLR2 in the host were required
for LLC metastasis after intravenous injection of LLC cells. Bio-
chemical analysis of LLC-conditioned medium led to the iden-
tification of an extracellular matrix proteoglycan, versican, as a
macrophage activator that acts on TLR2 and its co-receptors,
TLR6 and CD14 (33). Cordero et al. also demonstrated by using
a fly model that TNF/Egr expressed by tumor-associated hemo-
cytes (leukocytes in fly) was necessary and sufficient to trigger
TNF signaling in tumor cells for dMMP1 expression (37). In
the present study, we demonstrated that PC from TNFα / 
mice did not increase MCP-1 expression by LLC cells in vitro.
Transplantation of LLC cells into the flank of TNF /  mice
resulted in reduced MCP-1 serum levels, indicating that TNF
plays a critical role also in vivo in inducing MCP-1 production
by tumor cells. Importantly, the growth of LLC tumors was
slower in TNFα /  mice. A recent study by others showed that
anti-MCP-1 neutralizing antibody inhibited the growth of LLC
tumors (16). These findings suggest that MCP-1 is an impor-
tant downstream effector molecule of TNFα involved in cancer
progression.
In contrast to the role of TNFα, the role of MyD88 and TLRs
in LLC-mediated macrophage activation remains unclear. Co-
culture of LLC cells with PC fromTLR2 / , TLR4 / , TNR9 / 
or IL-1R1 /  mice increased MCP-1 mRNA expression by LLC
as efficiently as WT PC. MyD88-deficiency in macrophages
reduced MCP-1 expression and production by LLC cells in vitro,
but MyD88-deficiency did not reduce serum MCP-1 levels or
LLC tumor volumes as effectively as TNFα-deficiency in vivo.
These results suggest that other TLRs may mediate LLC-induced
macrophage TNFα production, and MyD88-independent
mechanisms may also play a role in vivo. Additional studies are
necessary to more precisely define the role of TLR signaling in
the activation of macrophages by LLC cells.
LLC cells were highly responsive to the TLR4 ligand LPS or
TNFα to express high levels of MCP-1. A human NSCLC cell
line, A549, also expresses and produces a high level of MCP-1 in
response to TNFα (38) (confirmed by our own study). In contrast,
4T1 breast cancer and B16 melanoma cells responded poorly to
the same stimuli and expressed only a low level of MCP-1. The
expression of TNFα was found in both 4T1 and LLC tumors;
thus, TNFα is available in both tumors and capable of stimulating
tumor cells to produce high levels of MCP-1. These findings sup-
port the hypothesis that the crosstalk between tumor and stromal
cells is tightly controlled by factors present in tumor microenvi-
ronments and these factors and the responsiveness of tumor cells
may determine the primary source of MCP-1 in each tumor.
It should be noted that in the present study, we used a tumor
transplantation model in which LLC cells were subcutaneously
injected into the flank ofmice. In addition, we used i.v. injection of
LLC cells as a model of lung tumors. Therefore, our results, while
they are valid, need to be interpreted with caution and further
validated in other tumormodels, in particular in orthotopic tumor
implantation models, to dissect the crosstalk between tumor and
stromal cells in producing tumor-promoting chemokines, such as
MCP-1. Recently, Weiss et al. reported an orthotopic model of
LLC (also known as 3LL) tumor in which very small numbers
of tumor cells were directly injected into the lung parenchyma
to generate a solitary pulmonary nodules (39). Resulting lung
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FIGURE 6 | The role of macrophage TLR2, TLR4, TLR9, and IL-1R1 in
MCP-1 mRNA expression by LLC cells. (A) One thousand LLC cells were
seeded into 12-well plates. After overnight incubation at 37°C, 1105 PC
from WT or TLR2 /  mice were added to the wells. After incubation at 37°C
for 5 days, total RNA was isolated and the expression of MCP-1 mRNA was
examined by Northern blotting (10µg per lane). (B) One thousand LLC cells
were seeded into 12-well plates. After overnight incubation at 37°C, 1105
PC from WT, TLR4 /  or IL-1R1 /  mice were added to the wells. After
incubation at 37°C for 5 days, total RNA was isolated and the expression of
MCP-1 mRNA was examined by Northern blotting (10µg per lane). (C) One
thousand LLC cells were seeded into 12-well plates. After overnight
incubation at 37°C, 1105 PC from WT or TLR9 /  mice were added to
the wells. After incubation at 37°C for 5 days, total RNA was isolated and the
expression of MCP-1 mRNA was examined by Northern blotting (10µg
per lane).
tumors were surrounded by normal lung parenchyma that grew
locally with the infiltration of fibroblasts and myeloid cells,
such as CD45+Gr-1medCD11bhigh myeloid-derived suppressor
cells, over time. Interestingly, the expression and production
of MCP-1 and MCP-3/CCL7 were markedly upregulated in the
lung tumors in this model. In our study, we also detected
the upregulation of MCP-1 expression in lung tumors formed
by intravenously injected LLC cells despite a relatively small
number of tumor specimen examined. Thus, it is important
to further analyze the mechanisms by which lung cancer cells
interact with stromal cells for tumor progression using a clin-
ically relevant orthotopic model and additional cancer cell
lines.
Naturally arising tumors are heterogeneous and may vary in
their capacity to respond to stimuli and produce mediators to
support tumor progression. Our study provided a novel mecha-
nism whereby tumors produce a high level of tumor-promoting,
proinflammatorymediators, such asMCP-1, in response to TNFα
released by macrophages, in tumor microenvironments. Better
understanding the complex interaction of tumor cells with cells
in stroma, such as macrophages, may provide opportunities to
develop additional anti-cancer therapies.
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